C/CPublished research associates this genotype with substantially reduced SLCO1B1 transporter function — associated with a clinically meaningful elevated risk of statin-associated muscle side effects (myopathy), particularly at higher simvastatin doses.
T/CPublished research associates this genotype with reduced SLCO1B1 transporter function, which can raise blood levels of some statins (notably simvastatin) and is associated with a moderately elevated risk of muscle-related side effects.
T/TTypical SLCO1B1 transporter function in published research — no added risk from this variant for statin-associated muscle side effects.
This is a pharmacogenomic finding with clinical dosing guidelines (CPIC). If you are prescribed a statin, share this result with your doctor or pharmacist — it may affect which statin or dose is recommended. Do not stop or change any medication on your own.
Source: SEARCH Collaborative Group, Link et al. 2008, New England Journal of Medicine — SLCO1B1 variants and statin-induced myopathy.